Sandwich, Kent, UK, 4th December 2023 / Sciad Newswire / Discovery Park Ventures (DPV) announces the expansion of its early-stage life science fund from £1m to £3m, in order to capitalise on exciting investment opportunities and support its existing portfolio. The fund’s investors have committed an additional £2m, which will also enable the fund to take larger stakes in companies that strongly align with its strategic objectives.
News
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR SIGNS CO-DEVELOPMENT AND EXCLUSIVE LICENCE OPTION AGREEMENT WITH LEADING GLOBAL MEDICAL PRODUCTS COMPANY FOR IN-HOUSE SPECIALITY HOSPITAL PRODUCT
Arecor-developed, Arestat™-enabled product is potentially first ready-to-dilute liquid formulation of a high-value oncology therapy
Seasoned Life Sciences pharmaceutical physician and leader joins the region’s Life Science & Healthcare membership organisation
Arecor Therapeutics plc
(“Arecor” or the “Group”)
ARECOR CONTINUES COLLABORATION WITH LILLY
Development of an enhanced formulation of Lilly proprietary product using Arecor’s formulation technology platform Arestat™
Cambridge, UK, 29 November 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, today announces that it has signed a further collaboration agreement with Eli Lilly and Company (“Lilly”).
Leading life sciences products and services provider - AMSBIO announce the launch of a custom service providing access to a suite of powerful spatial biology multi-omics profiling tools.
November 2023
Kadans Science Partner given green light for new purpose-built laboratory scheme in King’s Cross, London
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
- Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesis
- Refined focus on neurodegenerative disease targets
- Proceeds to be used to advance lead programme targeting FAN1 nuclease in Huntington’s Disease towards the clinic
Biocair, a leading specialist in cell and gene therapy logistics, is proud to announce its alliance with Pharma.Aero, a global cross-industry collaboration platform. Together, they are driving transformation in the cell and gene therapy (CGT) supply chain.
Cell and gene therapies are a revolutionary way to fight disease in that they offer patients complete personalization of medicine. These time-sensitive and life-changing medicines need logistics solutions as innovative as they are.
Source Genomics White Paper explores the transformative power of multi-omics in genomic research.
Multiomics combines the various ‘omics disciplines that make up the complex landscape of life science research. With the integration of genomic, transcriptomic, proteomic and epigenomic data, we obtain an advanced vision of the overarching framework behind all phenotypic outcomes.
AMSBIO has announced a new range of customizable ELISA assay kits designed to enable experienced researchers to achieve reliable and reproducible assay results.
With over 500 ELISA kits to choose from, the new range covers a wide variety of biological processes, targets, and sample types. Reagents such as matched antibody pairs and a micro-ELISA pre-plate have been carefully screened and validated to save you time and money.